Mylan has announced that it will invest up to $100 million annually over a five-year period to add a total of 500 new jobs to its work forces in Dublin and Galway, Ireland by 2016. The investment includes funding for R&D and manufacturing in solid dose and injectables in addition to the respiratory area. Mylan currently employs approximately 700 people in Ireland at Bioniche Pharma and at Gerard Laboratories, which markets Gerivent salbutamol (albuterol) MDIs.
Mylan CEO Heather Bresch commented, ”This investment in Mylan’s Irish operations and the growth of our capabilities in the country demonstrate our continued commitment to and confidence in our respiratory franchise and injectables platform, both of which are among Mylan’s many long-term growth drivers. Ireland also has proven to be a valuable location for Mylan, providing the company with access to a skilled and highly educated workforce that shares our strong work ethic and commitment to excellence. I would like to thank Prime Minister Kenny, Richard Bruton, Ireland’s minister for Jobs, Enterprise and Innovation, along with IDA Ireland, for all of their support. Importantly, I’d also like to recognize Mylan’s employees in Ireland for their hard work and dedication to our continued success.”
Prime Minister Enda Kenny said, “Mylan’s decision to expand in both Dublin and Galway is most welcome news. Mylan is a key member of the Irish pharmaceutical sector and one of the top suppliers in the country, providing the market with high quality generic pharmaceuticals and over-the-counter medicines. Today’s announcement, in addition to the company’s proven, 25-year track record as a top employer and reliable exporter in Ireland, demonstrates Mylan’s commitment to its Irish operations and recognition for the capabilities of its talented workforce. I would like to offer continued support of the Irish government, and IDA Ireland, to Mylan as it continues to grow in our country and as it further serves as an innovative contributor to the Irish economy.”
Read the Mylan press release.